<DOC>
	<DOC>NCT00240877</DOC>
	<brief_summary>To assess the safety of a vaccine in healthy adults prior to the release of the trivalent vaccine (FluMist).</brief_summary>
	<brief_title>Study to Evaluate the Safety of a Monovalent Vaccine of a New 6:2 Reassortant in Healthy Adults (AV024)</brief_title>
	<detailed_description>The primary study objective is to assess the safety of a monovalent vaccine of a new 6:2 reassortant in healthy adults prior to the release of the trivalent vaccine (FluMist). Safety will be demonstrated by similar fever rates (oral temperature ≥101°F) in vaccine and placebo recipients.</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1864 years of age (not yet reached their 65th birthday); In good health; Available by telephone; Ability to understand and comply with the requirements of the protocol; and Signed informed consent. Any condition, other than age, for which the inactivated influenza vaccine is indicated, including: chronic disorders of the pulmonary or cardiovascular systems, including asthma; chronic metabolic diseases (including diabetes mellitus) renal dysfunction, or hemoglobinopathies which required regular medical followup or hospitalization during the proceeding year; Acute febrile (&gt;100.0°F oral) illness or clinically significant respiratory illness within the 14 days prior to enrollment; Hypersensitivity to egg or egg protein; Signs or symptoms of any immunosuppressive or immune deficiency disease, including HIV infection, or ongoing immunosuppressive therapy; or an immunosuppressed individual living in the same household; Participation in another investigational trial within one month prior to enrollment or expected enrollment in another investigational trial during this study; and Any condition that in the opinion of the investigator, might interfere with the vaccine evaluation.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>November 2008</verification_date>
</DOC>